96 Tests PN: B511116

Components:

45x Ab-conjugated beads (S4P6 - Canine IL-6 ab-bead). PN: B511116A. One vial containing 100 µL of anti-canine IL-6 conjugated to AimPlex Bead S4P6

25x Biotin-detection Ab (Canine IL-6 Biotin-dAb). PN: B511116B. One vial containing 100 µL of biotinylated anti-canine IL-6.

Lyophilized Standard Mix-Canine Group 1 Panel A, 10-Plex. PN: KG10010. One vial containing lyophilized recombinant IFNγ, IL-2, IL-6, IL-8, IL-10, IL-12p40, IL-17A, MCP-1, SCF and TNFα. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Application: Optimal antibody pair and antigen standard for assaying Canine IL-6.  Can be multiplexed with other analytes in Canine Group 1.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 10 pg/mL

  • Quantitation range:

  • LLOQ: < 20 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Canine Group 1: Negligible

  • Sample volume: 15 µL/test

Description:

Interleukin-6 (Accession P41323) is a member of the interleukin cytokine family, though it displays some hormone-like properties that can affect many metabolic processes. IL-6 may act as a pro- or anti-inflammatory cytokine. It is primarily secreted by T-cells and macrophages to stimulate immune responses. It may be secreted during tissue damage or during bacterial infections. IL-6 is able to cross the blood-brain barrier. IL-6 supports the growth of B-cells and inhibits the proliferation of regulatory T-cells. It may also have the potential to improve anti-tumor activity in cancer immunotherapy.

References:

  1. Banks WA, Kastin AJ, Gutierrez EG. Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci. Lett. 1994; 179 (1-2): 53-56. Doi: 10.1016/0304-3940(94)90933-4.

  2. Ferguson-Smith AC, Chen YF, Newman MS, May LT, Sehgal PB, Ruddle FH. Regional localization of the interferon-beta 2/B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome. Genomics. 1988; 2(3): 203-208. Doi:10.1016/0888-7543(88)90003-1.

  3. Jones SA, Takeuchi T, Aletaha D, Smolen J, Choy EH, McInnes I. Interleukin 6: The biology behind the therapy. BMJ. 2018; 2(1): Doi:10.1136/conmed-2018-000005.

  4. Lin G, Wang J, Lao X, Wang J, Li L, Li S, Zhang J, Dong Y, Chang AE, Li Q, Li S. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother. 2012; 35(4): 337-343. Doi: 10.1097/CJI.0b013e318255ada3.